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ABSTRACT
INTRODuCTION: Chronic obstructive pulmonary disease (COPD) is one of the major causes of mortality 
and mortality affecting the whole world. In the inflammatory process, lectin is elevated and consequently,  
Galectin-3 expression is increased. This relation has been revealed by studies on coronary diseases. However, 
studies on the association of Galectin-3 with COPD and even other pulmonary diseases have been limited, al-
though it has been studied and described on cardiologic patients. For this reason, in this study Galectin-3 lev-
els in different stages of COPD patients were investigated and whether Galectin-3 could be a guide clinically.
MATERIAL AND METHODS: This is an observational prospective study, approved by local ethic committee 
(30112015-12), which included three groups of patients, COPD exacerbation, COPD stable and control 
group, admitted to tertiary healthcare between 01.09.2016 and 01.09.2017. 
RESuLTS: 137 subjects were included in the study. The mean age of patients in the study was 70.6. Galec-
tin-3 level in the group of COPD (exacerbation and stable) was significantly lower than the control group 
(p < 0.001). The Galectin-3 level was significantly lower in COPD exacerbation group than groups of stable 
COPD and control. And also, Galectin-3 level was significantly lower in stable COPD group than the control 
group (p values: 0.034, 0.001 and 0.013, respectively). The ROC analysis for the Galectin-3 levels between the 
COPD patients (exacerbation and stable) and the control group is shown in Figure 2 (AUC = 0.784). When 
the cut-off points of Galectin-3 is selected as 11.4; for this cut-off point, sensitivity is 83% and specificity is 
71% for this cut-off point (AUC: 0.79 %95 GA: 0.70–0.86 p < 0.001).
CONCLuSIONS: COPD is a disease with high mortality and morbidity and efforts are being made to identify its 
severity and exacerbations with various biomarkers. In this study, Galectin-3 levels were found to be lower in 
patients with stable COPD group according to the control group. In addition, galactin-3 levels were found 
to be lower in COPD exacerbation group according to both Stable COPD group and control group. Although 
a certain threshold value was found in this study, more studies are needed to determine this threshold value 
more precisely. However, it is clear that these data are promising.
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ABBREvIATIONS
AUC = Area under the ROC Curve
CMIA = Chemiluminescent microparticle  
immunoassay
COPD = Chronic obstructive pulmonary disease
FEV1 = Forced expiratory volume in 1 second 
FVC = Forced vital capacity
GOLD = Global Initiative for Obstructive Lung Disease
PFT = Pulmonary function test
ROC = Receiver operating characteristic
WHO = World Health Organization
INTRODuCTION
Chronic obstructive pulmonary disease (COPD) is 
one of the major causes of mortality and mortality 
affecting the whole world [1]. In the evaluation 
according to countries income estimates with the 
World Health Organization (WHO) data; COPD is 
the fifth death reason in the upper-income countries 
and the sixth death reason in the middle-low income 
countries and is responsible for 4.9–3.8% of deaths 
[1]. In the same report, COPD is located between 
the seventh and tenth row among the causes of 
incapacity to work [2].
According to the Global Initiative for Obstructive 
Lung Disease (GOLD) guidelines, COPD is a disease, 
which is seen with progressive irreversible airway 
obstruction that can affect other systems other than 
the lung and be prevented or treated. The COPD and 
its side effects can be avoided by taking measures 
such as non-use of cigarettes, reduction of occu-
pational inhaler substance exposure, prevention of 
complications and early diagnosis of the disease. 
However, COPD is a treatable disease despite having 
a progressive feature [3]. Various classifications have 
been proposed to regulate the treatment of the 
patient and estimate the survival time but the most 
used classification in the world was formed accord-
ing to the results of pulmonary function test (PFT), 
recommended by GOLD [3]. 
Although there are many different causes in the 
aetiology of COPD, the inflammation caused by in-
haled particulates and gases plays a key role in the 
pathophysiology [4]. This situation was clearly de-
fined in studies conducted, and now studies have 
focused on the relationship between the region, 
type and grade of inflammation and the severity of 
the disease. T-lymphocytes (predominantly CD8+ 
cells) and macrophages are present in the bronchial 
mucosa of COPD patients [4]. At the same time, 
airway obstruction correlates with the number of 
T lymphocytes [5]. However, the mechanism of this 
accumulation cannot yet be explained and the only 
known issue is that these cells and inflammation 
play a key role in the pathogenesis of COPD pa-
tients. As a result of this inflammation; increase 
in size of mucous glands in the submucosa, and 
hyperplasia / metaplasia and squamous metaplasia 
are seen in airway goblet cells [5].
Galectins are galactose-binding proteins and can 
enhance the proliferation of respiratory epithelial 
cells by limiting adhesion to the basement mem-
brane through competition with integrin receptors 
for the binding of laminin in the extracellular matrix 
[6]. It has also been shown to play a role in the 
cancer mechanism. Galectin-3, which is one of ten 
members of the galectin family, is a β-galactosidase 
binding protein. Galectin-3 is also activated from 
T lymphocytes, and it is expressed from the epi-
thelium, and dendritic cells such as macrophages 
and Kupffer cells. At the same time, extracellular 
Galectin-3 activates monocytes/macrophages, mast 
cells, neutrophils and lymphocytes and regulates 
relations of cell-cell and cell-matrix through these 
activations [7].
In the inflammatory process, lectin is elevat-
ed and consequently, Galectin-3 expression is in-
creased. This relation has been revealed by studies 
on coronary diseases [8]. However, studies on the 
association of Galectin-3 with COPD and even other 
pulmonary diseases have been limited, although 
it has been studied and described on cardiologic 
patients. For this reason, the authors of this study 
investigated Galectin-3 levels in different stages of 
COPD patients and whether Galectin-3 could be 
a guide clinically.
MATERIAL AND METHODS
This is an observational prospective study, approved 
by local ethic committee (30112015-12), which 
included three groups of patients, COPD exacer-
bation, COPD stable and control group, admitted 
to tertiary healthcare between 01.09.2016 and 
01.09.2017. The patients’ data were collected by 
the authors. The COPD exacerbation were patients 
admitted to emergency service; the COPD stable 
group, outpatients admitted to polyclinic of chest 
disease for COPD; the control group were healthy in-
dividuals admitted to different clinics of the hospital 
for control purposes. The exclusion criteria were age 
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under 18 years old, active infection, cancer history, 
pulmonary embolism, inability to get informed of 
consent due to neurological and psychological rea-
sons or tracheal intubation, absence of PFT results, 
and presence of active SVO. Studies exclusion criteria 
were defined as being under 18 years of age, active 
infection, presence of cancer history, absence of con-
sent (patients with neurological and psychological 
reasons or with intubation), pulmonary embolism, 
absence of PFT result and presence of active SVO.
Demographic and clinical data as well as PFT 
data (FEV1, FVC, and FEV1/FVC) were registered. 
At hospital admission, blood sample was taken, 
and Architect Galectin-3 assay was performed using 
the chemiluminescent microparticle immunoassay 
(CMIA) principle for the quantitative determination 
of Galectin-3 in human serum. Measurements were 
performed on the Abbott i1000 autoanalyzer.
61 patients were included in the COPD exac-
erbation group. In this group; PFT results of three 
patients were not found, and one patient was in-
tubated. For these reasons, 57 patients remained in 
this group. 
49 patients were included in the group of pa-
tients with stable COPD. In this group, 2 patients 
were diagnosed with pneumonia, and 2 patients 
were diagnosed with cancer. For these reasons, 
35 patients remained in this group. There were 
45 people in the control group. 
Statistical Analyses
Statistical analyses were performed using the IBM 
SPSS software version 24. The variables were inves-
tigated using visual (histograms, probability plots) 
and analytical methods (Kolmogorov-Simirnov/Shap-
iro-Wilk’s test) to determine whether they are nor-
mally distributed. Descriptive analyses were present-
ed using median and 25 percentiles 75 percen-
tile. The parameters were not normally distribut-
ed; “Kruskal Wallis” and “Mann-Whitney U” tests 
were conducted to compare these parameters, as 
well as to compare the ordinal variables. An overall 
%5 type-I error level was used to infer statistical 
significance. In additions, the capacity of serum ga-
lactin-3 values in predicting COPD diagnosis was 
analysed using ROC curve analysis. When a signifi-
cant cut-off value was observed, the sensitivity and 
specificity were presented. While evaluating the area 
under the curve, a 5% type-I error level was used to 
accept a statistically significant predictive value of 
the test variables.
RESuLTS
137 subjects were included in the study as COPD ex-
acerbations, stable COPD and control group. There 
were 57 patients in the COPD exacerbation group, 
35 patients in the stable COPD group and 45 people 
in the control group. The GOLD classifications ac-
cording to the PFT results of 92 patients who were 
in stable COPD and exacerbation group are given in 
Table 1.
The age data of the control group was not 
existing. The mean age of patients in the study 
was 70.6. The lowest age was 55 and the highest 
age was 91. There was no statistically significant 
difference between the groups when the age fac-
tor was compared according to the GOLD stand-
ards (p = 0.417). COPD exacerbation and stable 
COPD groups were similar in terms of age factor 
(p = 0.803)
In the control group, the patients’ gender in-
formation was not identified. On the other hand, 
there was no significant difference between COPD 
exacerbation and stable COPD groups in terms 
of gender (p = 0.107). There was no significant 
statistical difference between aetiologic causes of 
COPD exacerbation, stable COPD and control groups 
(p = 0.143).
Analysis with Galectin-3 is shown in Table 2. 
According to this data, Galectin-3 level in the 
group of COPD (exacerbation and stable) was 
significantly lower than the control group 
(p <0.001). 
Table 1. GOLD classifications according to PFT 
results of COPD patients
Patients Per cent
PFT Gold 1 13 14.1
PFT Gold 2 31 33.7
PFT Gold 3 28 30.4
PFT Gold 4 20 21.7
Total 92 100
Table 2. Galectin-3 levels of COPD exacerbation and 
Control groups total
Galectin-3
Median 25 Percentile 75 Percentile P value
Control 14.5 12.5 18.9
< 0.001*
COPD 5.85 2.1 12.85
*Mann-Whitney U Test
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Galectin-3 levels in groups of COPD exacerba-
tion, stable COPD and control are given in Table 3. 
According to this table, Galectin-3 level was sig-
nificantly lower in COPD exacerbation group than 
groups of stable COPD and control. And also, Ga-
lectin-3 level was significantly lower in stable COPD 
group than the control group (p values: 0.034, 
0.001 and 0.013, respectively).
Galectin-3 levels in COPD exacerbation and stable 
COPD groups are given in Figure 1 according to GOLD 
classification. There was no significant difference be-
tween the groups according to this table (p = 0.114).
The ROC analysis for the Galectin-3 levels be-
tween the COPD patients (exacerbation and sta-
ble) and the control group is shown in Figure 2 
(AUC = 0.784). 
When the cut-off points of Galectin-3 is se-
lected as 11.4; for this cut-off point, sensitivity is 
83% and specificity is 71% for this cut-off point 
(AUC: 0.79 %95 GA: 0.70–0.86, p < 0.001).
The ROC curve analysis for the Galectin-3 level 
of the COPD exacerbation group and the other pa-
tients (together with COPD exacerbation and con-
trol group) is given in Figure 3. For the detection 
of COPD exacerbation and other conditions, when 
the level of Galectin-3 was selected as 9.8; for this 
level, sensitivity was 75% and specificity was 74% 
(AUC: 0.76 %95 GA: 0.67–0.85, p < 0.001).
fIGuRE 3. ROC curve analysis for the Galectin-3 level of the 
COPD exacerbation group and other patients (COPD exacerbation 
and Control group)
Table 3. Galectin-3 levels of COPD exacerbation, COPD stable and Control groups
Galectin-3 Galectin-3
Median 25 Percentile 75 Percentile P value Pairwise Comparisons P value
COPD exacerbation 3.80 1.90 10.7
< 0.001
COPD exacerbation — COPD stable 0.034
COPD stable 8.20 4.85 17.00 COPD exacerbation —Control < 0.001
Control 14.50 12.50 18.90 COPD stable — Control 0.013
*Kruskal-Wallis Test
fIGuRE 2. ROC analysis of the Galectin-3 level between COPD 
patients (attack and stable) and control group
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DISCuSSION
COPD is an advanced age disease due to the cumula-
tive effect of factors that cause COPD [9]. This cumu-
lative effect is the reason why the mean age of COPD 
patients is high, and this is consistent with the litera-
ture. It is also seen that there are more patients with 
GOLD grade 2 and 3 when the patients with COPD 
are classified with GOLD. When patients with COPD 
were separated by GOLD classification according to 
the PFT values, it is seen that there are more patients 
whose GOLD stages are 2 and 3. The reason for this 
may be considered that COPD patients in GOLD-
Stage 1 are asymptomatic and take less diagnosis [10, 
11]. In addition, the ratio of patients in GOLD-Stage 
4 class can be thought to be relatively low due to 
morbid conditions associated with COPD [12]. The 
results of our study can be interpreted in this way.
Galectin-3 is an important element in the actin 
pathway of the phagocytic process and can play an 
important role in the production of glutathione, an 
intracellular antioxidant [13, 14]. Galectin produc-
tion is thought to play a role in the pathogenesis of 
COPD. In particular, Galectin-3 regulates apoptosis 
of epithelial and inflammatory cells and activation 
of neutrophil/macrophage [15].
Galectin-3 has been investigated in many types 
of cancer because of its association with cellular 
adhesion molecules. It has been proposed as a bi-
omarker to predict the endpoint in different types 
of thyroid cancers [16]. In addition, it has been 
reported in relation to the prognosis, severity and 
endpoint of cardiac diseases (especially heart failure) 
in both human and rat studies [17–19].
There is a limited study of the status of Galec-
tin-3 in COPD patients and most of them are studies 
with bronchoalveolar lavage at the cellular level. 
There is no study about the relationship between 
COPD and serum Galectin-3. In this study, serum 
Galectin-3 levels were significantly lower in COPD 
patients than in the Control group. And it was ob-
served that Galectin-3 was also produced less in 
exacerbation group among COPD groups. Howev-
er, according to the GOLD classification, there was 
no difference in terms of Galectin-3 levels between 
groups of COPD exacerbation and stable COPD.
In a study on samples taken with bronchoalveo-
lar lavage; active smoking and non-smoking patients 
with COPD, and active smoking and non-smoking 
volunteers were included. And in that study; Ga-
lectin-3 levels were found to be lower in COPD 
patients both smokers and non-smokers [13]. Sim-
ilarly, Galectin-3 levels were also found to be lower 
in patients with COPD in the presented study. But 
the presented study cannot be compared with that 
study, because the classification was not formed 
according to smoking status in the presented study.
The most powerful part of this study is the ROC 
curve analysis. When COPD patients were evaluated 
together with this analysis, the sensitivity and the 
specificity were found to be 83% and 71%, respec-
tively, for the value of 11.4 selected as a cut-off 
point of Galectin-3. However, the identification of 
the COPD exacerbation group is a priority for the 
authors. In the COPD exacerbation group, it was 
observed that sensitivity was 75% and specificity 
was 74% when the cut-off point of Galectin-3 was 
selected as 9.8. And these values can be indicated 
as acceptable values.
CONCLuSION
COPD is a disease with high mortality and mor-
bidity and efforts are being made to identify its 
severity and exacerbations with various biomark-
ers. In the presented study, Galectin-3 levels were 
found to be lower in patients with stable COPD 
group according to the control group. In addi-
tion, Galactin-3 levels were found to be lower 
in COPD exacerbation group according to both 
Stable COPD group and control group. Although 
a certain threshold value was found in this study, 
more studies are required to determine this thresh-
old value more precisely. However, it is clear that 
these data are promising. 
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